PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)- A UK PERSPECTIVE
Abstract
Authors
P Ducournau G Lewis A McDonald DR Millar E Sabate S Walzer